Clinical Research Directory

Inclusion Criteria:Inclusion Criteria: 1. Pathologically confirmed biliary tract cancer (including intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, distal cholangiocarcinoma) or colorectal cancer with liver metastases. 2. Received at least 2 cycles of prior systemic chemotherapy, with best response of stable disease (SD) followed by progression, or direct progressive disease (PD), indicating resistance to prior systemic chemotherapy. 3. Interval between the last cycle of prior systemic chemotherapy and initiation of HAIC rechallenge is at least 1 month. 4. At least one measurable target lesion in the liver per RECIST 1.1 criteria. 5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-2. 6. Adequate major organ function to meet the requirements for HAIC treatment. 7. Voluntarily signed informed consent form. \- Exclusion Criteria:Exclusion Criteria: 1. Extensive extrahepatic metastases (except for isolated, locally manageable pulmonary or lymph node metastases). 2. Contraindications to HAIC, including severe coagulopathy, complete portal vein main trunk tumor thrombus, or Child-Pugh class C liver function. 3. Prior local therapies (such as ablation or radiotherapy) before HAIC rechallenge that would interfere with target lesion assessment. 4. Concomitant other uncontrolled malignancies. 5. Pregnant or breastfeeding women. \-